Down-regulation of decorin, a transforming growth factor-beta modulator, is associated with scarless fetal wound healing
Copyright 2001 by W.B. Saunders Company..
PURPOSE: Transforming growth factor beta (TGF-beta) bioactivity has been implicated as a potential regulator of the transition from scarless healing to scar formation in fetal wounds. Decorin is an extracellular matrix proteoglycan that regulates TGF-beta bioactivity and assists in collagen fibrillogenesis. To determine its role in scarless repair, the authors examined decorin expression in fetal fibroblasts, skin, and wounds.
METHODS: A single, full-thickness, 2-mm open wound was created on the dorsal surface of fetal rats at 16.5 days (E16) and 18.5 days (E18) gestational age (term, 21.5 days [E21]). Wounds were harvested at 24 and 72 hours (n = 12 wounds per time-point). Nonwounded fetal skin at E17, E19, and E21 was harvested for analysis of decorin expression during skin development and as controls for wounds. In addition, fetal (E14, E18) and adult dermal fibroblasts were cultured for in vitro analysis. Reduced-cycle, specific primer, reverse transcriptase polymerase chain reaction was performed to quantitate decorin expression.
RESULTS: Decorin expression increased rapidly with increasing gestational age in both fetal fibroblasts and skin. Expression was increased 22-fold in E18 fibroblasts (P <.002) and 300-fold in adult fibroblasts (P <.001) compared with E14 fibroblasts. In skin, expression increased 74% (P <.01) during the fetal wound healing transition period between E17 and E19. However, in E16 wounds (scarless), decorin expression decreased 59% (P <.006) at 24 hours and 45% (P <.02) at 72 hours. Decorin expression did not change in E18 (scar) wounds at 24 and 72 hours (P >.05).
CONCLUSIONS: Early gestation fetal fibroblasts and fetal skin express decorin at lower levels than late gestation fetal and adult fibroblasts and skin. Decorin expression is down-regulated in scarless (E16) compared with scar (E18) wounds. Thus, increased decorin expression is associated with both skin development and scar formation. Conversely, decreased decorin expression is associated with scarless repair.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2001 |
|---|---|
| Erschienen: |
2001 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Journal of pediatric surgery - 36(2001), 11 vom: 27. Nov., Seite 1666-71 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Beanes, S R [VerfasserIn] |
|---|
| Themen: |
Decorin |
|---|
| Anmerkungen: |
Date Completed 07.03.2002 Date Revised 10.07.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM115798951 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM115798951 | ||
| 003 | DE-627 | ||
| 005 | 20231222172922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231222s2001 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0386.xml |
| 035 | |a (DE-627)NLM115798951 | ||
| 035 | |a (NLM)11685698 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Beanes, S R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Down-regulation of decorin, a transforming growth factor-beta modulator, is associated with scarless fetal wound healing |
| 264 | 1 | |c 2001 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2002 | ||
| 500 | |a Date Revised 10.07.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2001 by W.B. Saunders Company. | ||
| 520 | |a PURPOSE: Transforming growth factor beta (TGF-beta) bioactivity has been implicated as a potential regulator of the transition from scarless healing to scar formation in fetal wounds. Decorin is an extracellular matrix proteoglycan that regulates TGF-beta bioactivity and assists in collagen fibrillogenesis. To determine its role in scarless repair, the authors examined decorin expression in fetal fibroblasts, skin, and wounds | ||
| 520 | |a METHODS: A single, full-thickness, 2-mm open wound was created on the dorsal surface of fetal rats at 16.5 days (E16) and 18.5 days (E18) gestational age (term, 21.5 days [E21]). Wounds were harvested at 24 and 72 hours (n = 12 wounds per time-point). Nonwounded fetal skin at E17, E19, and E21 was harvested for analysis of decorin expression during skin development and as controls for wounds. In addition, fetal (E14, E18) and adult dermal fibroblasts were cultured for in vitro analysis. Reduced-cycle, specific primer, reverse transcriptase polymerase chain reaction was performed to quantitate decorin expression | ||
| 520 | |a RESULTS: Decorin expression increased rapidly with increasing gestational age in both fetal fibroblasts and skin. Expression was increased 22-fold in E18 fibroblasts (P <.002) and 300-fold in adult fibroblasts (P <.001) compared with E14 fibroblasts. In skin, expression increased 74% (P <.01) during the fetal wound healing transition period between E17 and E19. However, in E16 wounds (scarless), decorin expression decreased 59% (P <.006) at 24 hours and 45% (P <.02) at 72 hours. Decorin expression did not change in E18 (scar) wounds at 24 and 72 hours (P >.05) | ||
| 520 | |a CONCLUSIONS: Early gestation fetal fibroblasts and fetal skin express decorin at lower levels than late gestation fetal and adult fibroblasts and skin. Decorin expression is down-regulated in scarless (E16) compared with scar (E18) wounds. Thus, increased decorin expression is associated with both skin development and scar formation. Conversely, decreased decorin expression is associated with scarless repair | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Decorin |2 NLM | |
| 650 | 7 | |a Extracellular Matrix Proteins |2 NLM | |
| 650 | 7 | |a Proteoglycans |2 NLM | |
| 650 | 7 | |a Transforming Growth Factor beta |2 NLM | |
| 700 | 1 | |a Dang, C |e verfasserin |4 aut | |
| 700 | 1 | |a Soo, C |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Urata, M |e verfasserin |4 aut | |
| 700 | 1 | |a Ting, K |e verfasserin |4 aut | |
| 700 | 1 | |a Fonkalsrud, E W |e verfasserin |4 aut | |
| 700 | 1 | |a Benhaim, P |e verfasserin |4 aut | |
| 700 | 1 | |a Hedrick, M H |e verfasserin |4 aut | |
| 700 | 1 | |a Atkinson, J B |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenz, H P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pediatric surgery |d 1966 |g 36(2001), 11 vom: 27. Nov., Seite 1666-71 |w (DE-627)NLM00001902X |x 1531-5037 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2001 |g number:11 |g day:27 |g month:11 |g pages:1666-71 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2001 |e 11 |b 27 |c 11 |h 1666-71 | ||